Glucagon receptor (GCGR) antagonists have been shown to improve glucose regulation without increased risk of hypoglycaemia in both type 1 and type 2 diabetes [18–20], and to increase plasma levels of glucagon-like peptide 1 and glucagon, possibly as a result of alpha cell hyperplasia, which results in increased glucagon-like peptide 1/glucagon production/processing in pancreatic alpha cells [18, 21]. The gene discussed is GCG; the disease is Hypoglycemia.